ARWR Stock News & Catalysts – Arrowhead Pharmaceuticals

FEATURED

Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences

New

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming investor events:2026 Jefferies Global Healthcare Conference in London – November 16-19,

Summary

Nov 9, 2026, 4:00 PM ·Business Wire

RECENT

Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates

New

ARO-DIMER-PA Data Demonstrating Simultaneous Reductions in LDL Cholesterol and Triglycerides at American Heart Association Scientific Sessions 2026 Pooled SHASTA-3 and SHASTA-4 analysis showed plozasiran reduced

Nov 7, 2026, 4:15 PM ·Business Wire

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

- Existing $400 million facility prepaid at a $68 million discount to the contractual minimum repayment amount - New $400 million term loan priced at SOFR plus 5.50% - Debt has no scheduled amortization payments or

Nov 4, 2026, 7:30 AM ·Business Wire

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on November 12, 2026, at 4:30 p.m. ET to discuss its financial results for the 2026 fiscal year ended

Nov 3, 2026, 4:00 PM ·Business Wire

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

– Detailed Results from the Phase 1/2a Study of ARO-DIMER-PA, the First Dual-Functional Investigational RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia, Will Be Presented at Late-breaking Featured Science

Nov 2, 2026, 7:30 AM ·Business Wire

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation for REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglyceride levels in adult patients with Familial

Oct 27, 2026, 11:36 AM ·Business Wire

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

Arrowhead’s TRiM™ platform achieves clinical validation for delivery of siRNA that crosses the blood-brain barrier after subcutaneous injection ARO-MAPT demonstrates mean cerebrospinal fluid total tau reduction of

Oct 14, 2026, 7:30 AM ·Business Wire

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

- FDA STAR pilot program aims to shorten the time from complete supplement submission to the action date to allow earlier patient access to therapies that address an unmet medical need Arrowhead Pharmaceuticals, Inc.

Oct 7, 2026, 7:30 AM ·Business Wire

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

– ARO-MAPT utilizes the Targeted RNAi Molecule (TRiM™) platform designed for subcutaneous administration and systemic delivery to the CNS by crossing the blood-brain barrier – Arrowhead Pharmaceuticals, Inc.

Sep 29, 2026, 7:30 AM ·Business Wire

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

- ARO-DIMER-PA achieved deep and durable silencing of two genes with a single RNAi molecule - Mean maximal single dose reductions in serum PCSK9 of 72% and APOC3 of 88% - Clinical validation further demonstrates

Sep 15, 2026, 7:30 AM ·Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming investor events: 2026 Cantor Global Healthcare Conference – September 9-11, 2026 Type:

Sep 3, 2026, 7:30 AM ·Business Wire

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of plozasiran-treated patients achieved triglycerides below thresholds

Aug 30, 2026, 11:30 AM ·Business Wire

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

- Detailed results from the Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia will be presented as a HOT LINE Late-Breaking Science Session on August 30, 2026 - -

Aug 24, 2026, 7:30 AM ·Business Wire

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

REDEMPLO® (plozasiran) is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS), diagnosed either based on clinical

Aug 17, 2026, 9:33 AM ·Business Wire

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

- Conference Call and Webcast Today, August 4, 2026, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2026 third quarter ended June 30, 2026. The Company

Aug 4, 2026, 4:01 PM ·Business Wire

Arrowhead Pharmaceuticals, Inc. ARWR · News